NSCLC

[Cell Death & Disease] Scientists assessed priming of primary patient NSCLC tumor cells on drugs from a clinically relevant oncology combination screen.

[Cell Death & Disease] Investigators demonstrated that miR-4293 expression was markedly enhanced in lung carcinoma tissue and cells and miR-4293 promoted tumor cell proliferation and metastasis but suppressed apoptosis.

[Histology and Histopathology] Scientists used NSCLC tissues, as well as cell lines to elucidate the expression and location of circRIP2 in NSCLC. They also established the circRIP2 overexpression cells A549-circRIP2 and repression cells HCC827-shcircRIP2 for further functional and mechanism studies.

[Chemical Biology & Drug Design] The authors determined the efficacy of pyronaridine in four different NSCLC cell lines and explored its mechanism in H1975.

[Agilent Technologies Inc.] Agilent Technologies Inc. announced that the company’s PD-L1 IHC 22C3 pharmDx assay is now labeled for expanded use in patients with non-small cell lung cancer (NSCLC) in the European Union.

[Nature] Scientists identified mutation-associated neoantigens (MANA)-specific T cell clones using the MANA functional expansion of specific T cells assay3 in neoadjuvant anti-PD-1-treated non-small cell lung cancers.